Biocon Sees Approvals Unlocking $1 Billion Biosimilar Sales
(Bloomberg) -- Biocon Ltd., the only Indian drugmaker to win approval to sell copies of a biologic drug in the U.S., expects its business in that nascent sector will generate $1 billion in revenue by 2025 as it clears further regulatory hurdles this year.
The company's other leading drug candidates are back on track for approval after hiccups in the U.S. and Europe, said Managing Director Kiran Mazumdar-Shaw in an interview. Biocon is also exploring the sale of part of its stake in its publicly traded contract research arm, Syngene International Ltd., to fund its growing ambitions in the biologics business, she said. The stake is worth about $1.2 billion.
Three more approvals Biocon now expects this year in the U.S. and Europe would expand its presence in the pioneering field of biosimilars -- cheaper copies of biologic drugs that promise a new way to cut health-care costs and put billions of dollars in sales now going to brand name medicines up for grabs.
With its partner Mylan NV, Bengaluru-based Biocon holds one of just nine coveted approvals for a biosimilar product in the U.S. The company intends to build on its early lead, Mazumdar-Shaw said, plowing its biosimilars revenue into developing a broader portfolio of the medicines with Mylan and a new partnership with Novartis AG.
Biocon shares slipped 0.4 percent to 576.85 rupees a share at 10:18 a.m. in Mumbai on Tuesday.
U.S. authorities have told the company they will decide by June on Biocon's application to sell a version of Amgen Inc.'s multi-billion dollar chemotherapy drug Neulasta, after approval was delayed last year by a request for more information, she said.
Mazumdar-Shaw also said she's expecting the European drug regulator to re-inspect Biocon's Bengaluru facility sometime this month, opening the possibility the company's versions of both Neulasta and Roche Holding AG's blockbuster cancer drug Herceptin could win European approval by September. Biocon had to withdraw its European applications in August after authorities found problems at the plant in Bengaluru, formerly known as Bangalore, that required correcting.
"We have at least a five-year head start" in biosimilars compared with other Indian drugmakers, Mazumdar-Shaw said. “Now you're seeing the market opportunity.” Profit from Biocon's version of Herceptin, already approved in the U.S., should start to hit in about two years, she said.
That may not be fast enough as Biocon's current slate of drugs in development will need about $1 billion in investment at around the same time. The company is exploring fund-raising options, including selling some of its 73 percent stake in Syngene International, or allowing investors to buy a stake in its biosimilars subsidiary directly through a public offering, she said.
To contact the reporter on this story: Ari Altstedter in Mumbai at aaltstedter@bloomberg.net.
To contact the editors responsible for this story: K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland
©2018 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.